Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
Kate Therapeutics logo — New Hope for Patients with Muscle and Heart Disease

Kate Therapeutics

New Hope for Patients with Muscle and Heart Disease

Founded 2020 United States San Diego, United States 48 employees Acquired Total: $1.17B Biotechnology, Health Care +1

General Information

Company Name Kate Therapeutics
Founded Year 2020
Location United States San Diego, United States
Employees 48
Industries Biotechnology, Health Care, Health and Wellness
Funding Stage Acquired
Business Model B2B, B2D
Revenue Model Licensing, Product Sales
Social

BounceWatch is an independent company data service, not affiliated with Kate Therapeutics. To contact Kate Therapeutics, visit katetherapeutics.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Kate Therapeutics compare?

A PDF of Kate Therapeutics and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Kate Therapeutics soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Kate Therapeutics

Kate Therapeutics (KateTx) is a pioneering player in the biotechnology sector, focusing on groundbreaking solutions for genetically defined muscle and heart diseases. Founded in 2020, this United States-based company is spearheading the development of adeno-associated virus (AAV)-based gene therapies.

The company's innovative technology platforms are designed to overcome significant limitations of existing gene therapies, such as enhancing tissue-specific delivery and improving gene regulation. This could lead to heightened efficacy and safety of gene therapies while expanding the range of treatable targets that are currently challenging to address.

Strengthening its financial position, KateTx secured a robust $51.00M Series A investment on 08 June 2023. The funding round was led by strategic investors like Versant Ventures, Westlake Village BioPartners, UF Innovate Ventures, and OUP (Osage University Partners). These partnerships highlight strong investor confidence in KateTx's potential to transform patient outcomes in health care.

Business keywords: gene therapies, adeno-associated virus, AAV-based technology, muscle diseases, heart diseases, tissue-specific delivery, gene regulation, genetically defined diseases, novel technology platforms, efficacy improvement, safety enhancement, broader drug targets, patient-focused approach

Services & Products

Innovative Medicine Development
Research & Development
Clinical Trials
Therapeutic Solutions
Gene Therapies

Target Customers

Patients Healthcare Professionals Caregivers Researchers Investors

Funding Rounds & Investors (4)

View All
Funding Stage Amount Investors Lead Investors Date
Acquisition $1.10B 1
Novartis
Novartis
01 Nov 2024
Series B $21.78M -
01 Aug 2024
Series A $51.00M 4
Osage University Partners Versant Ventures Westlake Village BioPartners
Osage University Partners, Versant Ventures +2
01 Jun 2023
Spinout Undisclosed 3
University of Florida
University of Florida, Massachusetts Institute of Technology +1
01 Jan 2020

Kate Therapeutics Alternatives & Competitors

View All Alternatives
Kate Therapeutics vs
Renovacor
Renovacor

Advancing transformative therapies for cardiovascular disease

Post-IPO Equity
6 employees
Biotechnology, Health Care
Compare Kate Therapeutics vs Renovacor
Kate Therapeutics vs
Hunterian Medicine
Hunterian Medicine United States

Advancing cures for genetic diseases with innovative CRISPR delivery technology

Grant
6 employees
Biotechnology, Health Care
Compare Kate Therapeutics vs Hunterian Medicine
Kate Therapeutics vs
Rampart Bioscience
Rampart Bioscience United States

Leading a new era of effective, safe and accessible gene medicines.

Series A
28 employees
Biopharma, Biotechnology
View all alternatives

FAQ About Kate Therapeutics

New Hope for Patients with Muscle and Heart Disease
Kate Therapeutics was founded in 2020.
Kate Therapeutics is headquartered in San Diego, United States.
Kate Therapeutics operates in Biotechnology, Health Care and Health and Wellness. Its work centres on gene therapies, adeno-associated virus, AAV-based technology and muscle diseases. Its customers include Patients, Healthcare Professionals and Caregivers.
Kate Therapeutics has a B2B and B2D business model. Its revenue comes from Licensing and Product Sales.
Kate Therapeutics has approximately 48 employees.
Kate Therapeutics has completed 4 funding rounds, raising a total of $1.17B. The latest funding stage is Acquired.
Kate Therapeutics offers: Innovative Medicine Development, Research & Development, Clinical Trials, Therapeutic Solutions, Gene Therapies.
Top alternatives and competitors to Kate Therapeutics include Renovacor, Hunterian Medicine, Rampart Bioscience, MorphoSys, Vertex Pharmaceuticals. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Kate Therapeutics and Renovacor are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Kate Therapeutics, https://bouncewatch.com/company/kate-therapeutics, updated 20 July 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout